Frequently asked questions

Peptidos.eu currently ranks #1 in our European list, scoring 4.15 out of 5 against our published rubric. The Denmark-based vendor leads on pre-purchase third-party Certificates of Analysis and broad payment options including six cryptocurrencies; its main trade-offs are a smaller catalogue and a 24-hour support window. Particle Peptides (Slovakia, 3.9/5) and Primal Peptides (Netherlands, 3.45/5) round out the top three. The full European ranking covers 21 vendors and 46 independent lab tests.

Peptide Partners is the top-ranked US vendor, scoring 4.25 out of 5 on our methodology. Their multi-lab third-party verification covers purity, endotoxin, heavy metals, and sterility, paired with reliable domestic shipping; the main trade-off is a $400 free-shipping floor. Orbitrex Peptides (Texas, also 4.25/5) and Sports Technology Labs (Connecticut, 4.0/5) follow. The full US ranking evaluates 18 vendors against 52 independent lab tests.

PeptIQ leads our peptide app rankings with a score of 4.1 out of 5. It offers native iOS, Android, and web parity, free reconstitution and dosing math, and Apple Health integration; the main trade-off is its AI protocol layer, which expands the privacy and medical-posture audit surface. Smart Peptide Tracker (Android, 4.1/5) and PeptideCalc.io (iOS, 3.8/5) are the other top picks. Each app is tested for at least 30 days against a fixed battery of 15 to 20 reference dosing scenarios.

Nine biohackers and researchers based in the United States, Germany, and Switzerland. We met through forums, lab work, endurance sports, and longevity meetups. None of us is a doctor; a few have published peer-reviewed work in adjacent fields.

When the peptide boom hit, the ratio of marketing copy to honest information went sideways. Pepsider began as a shared doc among friends and became a public guide so accurate sourcing could compete with influencer noise.

Independent peptide shop rankings for the EU and US, peptide app reviews, and plain-language research write-ups grounded in peer-reviewed literature and clinical trial registries - all held to the same editorial standards.

We do not rank vendors we have not ordered from, review compounds we have not researched, remove content because vendors ask, accept paid placements, ghostwrite for shops, or claim medical, legal, or pharmacy credentials we do not hold.

Evidence quality and legal status vary widely between peptides and jurisdictions. Nothing here is medical advice; when literature is thin or hype outweighs data, we state that plainly.

The project is fully self-funded by the nine contributors: no advertising, sponsored editorial placements, or vendor relationships. We order from peptide shops anonymously with our own money; there is no paid tier, featured slot, or way to buy a rank. For apps, we buy every subscription and one-time unlock ourselves, decline developer promo codes for scored reviews, and refuse paid placement—where affiliate links appear on an entry, they are disclosed and do not influence scores or ordering. Publishing stays deliberately slow so each list is work we still stand behind.

Vendors are scored on a 1–5 anchored rubric with fixed weights: Testing Standards (35%), Trust (25%), Shipping & Reship Policy (15%), Value (15%), and Support & Transparency (10%). Apps use a separate six-criterion rubric, also 1–5 with anchors: Functionality (30%), Privacy (25%), Reliability (20%), UX & platform coverage (15%), Pricing (5%), and Safety content (5%). Anchored scoring ties every number to verifiable evidence—two reviewers grading the same vendor or app should reach the same result—and app composites use weighted sums with no hidden qualitative tiebreakers beyond explaining ties. The full write-ups live in our methodology (vendor and app sections) in version v5.0.

The methodology is identical — same criteria, weights, and anchors. What changes is the regional baseline for Shipping: a US vendor is scored on delivery to US buyers, a European vendor on delivery to European buyers. Testing, Trust, Value, and Support are region-neutral and directly comparable across both lists. Shipping scores are not, by design.

Because peptide legality is a buyer-side question, not a vendor-quality question. It varies by jurisdiction, intended use, and research-vs-human framing — none of which the vendor controls or we can verify. We assume readers have done their own legal due diligence for where they live.

UX & Platform Coverage is 15% of the composite. A polished iOS-only app that nails dosing math, ships reliable notifications, and keeps data local will beat a wide-footprint app that misses on the heavier functionality and privacy axes. Breadth never compensates for math errors.

Pepsider re-scores every ranked vendor and app on a quarterly cadence, with the most recent updates published in April and May 2026. Documented corrections submitted with verifiable evidence — Certificates of Analysis, screenshots, or other primary sources — jump the queue for the next scoring round. Vendors may also request a retest at their own cost, conducted by a different lab from our independent panel, with both results published.

Yes — reader-submitted CoAs and order reports are reviewed and, where verifiable, factored into the next scoring cycle for both our European and United States vendor lists. They are weighted lower than our own test orders and named lab reports, but consistent reader signal does move scores over time. Use the contact form to send documentation, CoAs, or order notes.

Third-party CoAs from independent labs like Janoshik and Auxilium are the strongest purity signal we consistently see. Reliability depends on the methods (HPLC for purity is the floor; mass spectrometry for identity and endotoxin testing strengthens the signal), whether the certificate matches the batch you are buying—not a stale generic report—and whether you can review it before purchase rather than only on request afterward. Named third-party labs used across many vendors also have industry-wide reputation at stake. In-house testing is not worthless as documentation, but the vendor controls what is tested and published, and a failed batch costs them directly—so we treat it as a starting point, not proof. Our rubric caps how high a vendor can score on Testing when work stays in-house only, regardless of track record—for example, a multi-year European record still hits that ceiling without independent lab CoAs.

Janoshik Analytical is a Czech testing laboratory widely used for third-party HPLC and mass spectrometry on peptides. It operates independently of the vendors it tests, and researchers can cross-check CoAs against its own database and against thousands of other documents in circulation—making wholesale forgery much harder. In Europe it has become an informal community standard: large enough to recognize, small enough to audit. Limitation: coverage people summarize as “Janoshik tested” usually reflects identity and purity work—not endotoxin, bioburden, or sterility—so it is not by itself a sterility guarantee.

Finnrick is an independent platform publishing batch-level grades (A through F) on US peptide vendors, with samples cross-checkable against its own database. It focuses on identity and purity — endotoxin and sterility aren't standard coverage, so "Finnrick A" reflects composition, not sterility assurance.

A CoA is the laboratory report that documents what's actually inside a vial — typically identity confirmation (this is the peptide on the label), purity percentage, and increasingly contamination screening for endotoxins, residual solvents, and water content. Without a CoA tied to your specific batch number, you're trusting the vendor's marketing rather than verifying the chemistry. A CoA from an independent, named laboratory is the single most useful trust signal in this market.

HPLC (high-performance liquid chromatography) measures purity by separating the peptide from impurities and quantifying each peak — it answers "how much of this sample is actually the target compound?". Mass spectrometry confirms identity by measuring molecular weight to verify the structure matches the labeled peptide — it answers "is this the right molecule at all?". Top-tier vendors run both on every batch; methodology that includes only one leaves a meaningful blind spot.

Three checks. First, the CoA should reference the same batch or lot number printed on your vial. Second, the issue date should predate your shipment, not be backdated to a generic "current batch". Third, if the laboratory is named, the document should be either hosted on that lab's domain or verifiable on request — vendors who supply only a screenshot with no path to source verification are essentially asking you to trust an unverifiable image.

In April 2026, questions surfaced about whether Liquilabs — the lab Particle cited for batch testing — was operating with sufficient independence from the vendor. Particle has not published a satisfactory rebuttal or moved testing to an unaffiliated lab. The Trust score reflects that unresolved status.

Yes. Vendors can request a retest at any time at their own cost, conducted by a different lab from our independent partner panel. We publish both results.

In regulated industries, trust is partly outsourced to government oversight - pharmacy boards, agency inspections, legal recourse. In the European peptide market, none of that infrastructure protects buyers, so trust gets reconstructed from the bottom up: years of consistent shipments, transparent ownership, named laboratory partners, and how a vendor responds when something goes wrong. It is slower to build and considerably harder to fake than a regulated equivalent.

Of course they can, and Primal Peptides is a recent example. But longevity proves something specific that a new vendor by definition cannot yet demonstrate: the absence of a major incident across thousands of orders and many years of operation. New vendors deserve a fair hearing, but the Trust score appropriately reflects that certain questions about consistency simply require time to answer.

A few patterns reliably separate the two. Real users mention specific compounds, dosages, and timeframes; astroturf reviews tend toward generic ("great service, fast shipping"). Real discussion happens on independent forums - Reddit, Eroids, peptide-specific Discords - where the vendor doesn't control moderation. And real endorsements survive criticism: if a vendor's defenders vanish the moment a credible complaint surfaces, that itself is the signal.

The accusation is one data point; the response is two. Vendors who issue detailed, specific public statements addressing concrete claims - Particle Peptides' on-record reply to recent Reddit allegations about Liquilabs is a current example - signal that they take their reputation seriously enough to defend it in writing. Vendors who go silent, delete threads, or pivot to vague reassurances are signaling something quite different. Wait for the response, then weigh both.

Trustpilot sits at the bottom of our trust composite because vendor-solicited reviews dominate the platform and there is little meaningful gating on reviewer authenticity. We use it only as corroboration when other signals already agree—it never decides a verdict on its own. Higher weight goes to independent blind-testing programs, long-running reviewer dossiers, and vetted Discord communities with active moderation; Reddit sits in the middle, read skeptically for coordinated promotion. As a buyer, still treat Trustpilot as one signal among several: look for public, substantive replies to complaints and whether positive reviews are specific enough to sound real. Volume matters less than how criticism is handled in the open.

The shop at paradigm-peptide.com shares branding with the defunct Paradigm Peptides LLC, a separate operation that has since closed. Order receipts, support contacts, and ownership signals all point to a different entity. The Trust score reflects that ambiguity until clearer disclosure surfaces.

Before 2021, UK-to-EU peptide shipments moved freely inside the customs union. After Brexit, every UK-to-EU package crosses a customs border, which means longer delivery windows, occasional duty or VAT charges on arrival, and a non-trivial seizure rate at major continental hubs. UK vendors can still serve EU buyers, and many do so well, but the border friction itself is not something a vendor can fully eliminate - only manage through clear reship policies.

Less than the marketing suggests. "Reship" usually means the vendor agrees to send a replacement shipment if an order is seized at customs, typically after the buyer provides a seizure notice. The important caveats: most policies cap how many reshipments per order, exclude certain destinations entirely, and require photographic or written proof. A policy is meaningfully better than no policy, but read the specifics before assuming you're insured against every outcome.

The EU-27 is a single customs union - packages move between member states without crossing a hard border, which dramatically reduces seizure rates, delivery times, and surprise duty charges. A vendor dispatching from Slovakia, the Netherlands, Germany, Spain, Romania, or Denmark to another EU member is essentially shipping domestically. UK vendors lost that structural advantage in 2021, which is why post-Brexit friction recurs throughout the rankings above.

For most lyophilized (freeze-dried) peptides, no - the dry form remains reasonably stable at room temperature for the few days a typical EU shipment takes. Pre-mixed or reconstituted products are a different story and genuinely benefit from cold-chain logistics. Temperature-controlled shipping is a useful trust signal that the vendor takes handling seriously, but it shouldn't be treated as a strict requirement for every order, especially for short EU-internal routes.

Stealth packaging means the outer parcel doesn't visually advertise its contents - generic boxes, no vendor branding, neutral return addresses, no peptide-specific labelling. It matters most on cross-border shipments where customs officers triage thousands of parcels partly by appearance, and for buyers in shared-mailbox situations who'd prefer the contents stay private. For domestic EU-to-EU shipping it's a nice-to-have; for UK-to-EU, it's a meaningful seizure-rate factor worth weighting.

In this market, lowest price strongly anti-correlates with synthesis quality. A 99% purity peptide cannot be honestly delivered at the lowest price tier - the math of synthesis cost doesn't allow it. We treat that gap as a quality signal, not a value signal.

A 5 mg vial at €40 looks cheaper than a 10 mg vial at €60, but the second is meaningfully better value — €6 per mg versus €8 per mg. Price-per-milligram normalizes across vial sizes and lets you compare vendors directly, which is the single most useful metric for genuine value comparison. Most reputable vendors structure their pricing so larger vials carry a 10–15% per-mg discount, which is worth checking before defaulting to the smaller size.

Peptide vendors are classified as high-risk by traditional banks, so card processing is expensive, unstable, and frequently shut down without notice. Crypto bypasses all of that — irreversible transactions, no chargebacks, no merchant-account dependencies. From the buyer's perspective it offers privacy and reliability, but you also lose chargeback protection if something goes wrong, so weigh that trade-off against how much you trust the specific vendor before defaulting to it.

Sometimes, sometimes not. A 20% recurring discount code that's effectively always available is just a higher base price with built-in margin for the discount. A genuine seasonal sale or single-use first-order incentive on top of stable everyday pricing is real value. The simple test: check the same product's price across several months — if "discounted" prices are the only prices you ever see on that vendor, the discount isn't really a discount.

Three reasons. EU-based vendors absorb higher manufacturing and compliance costs — European Pharmacopoeia standards, EU jurisdiction overheads, more rigorous testing where applied. They also avoid the customs friction that destroys effective value on US imports, since a cheap US vial seized at the border is infinitely expensive. And payment processing plus EU-internal logistics simply cost more than equivalent US domestic infrastructure, which gets passed through into sticker prices.

Almost always baked in — peptide vendors don't absorb shipping costs as charity. Free-shipping thresholds (over €100, over €150) are real incentives because they shift behavior toward larger orders where the per-milligram price drops anyway. Unconditional free shipping is usually offset by slightly higher product pricing across the catalog. The honest comparison is all-in delivered cost per milligram, not line-item shipping fees treated in isolation.

The clearest signal is named human responses rather than anonymous templates — vendors where the same support agent's name appears across multiple resolved tickets, where replies actually address the specific complaint instead of redirecting to FAQ pages, and where disputes get worked out on public review platforms rather than disappearing into private email. Speed matters less than substance: a thoughtful 24-hour reply that resolves the issue beats an instant reply that doesn't.

Because in an unregulated market, what a vendor chooses not to disclose is often more informative than what they do. Vendors who name their laboratory partners, identify their manufacturing source, and publish detailed testing methodology are accepting accountability that can be independently verified. Vendors who substitute marketing language — "premium pharmaceutical-grade", "GMP partners", "rigorous quality control" — for specifics are usually obscuring something that wouldn't survive direct scrutiny.

Treat them as expressions of intent rather than guarantees. A clearly written reship policy, refund process, or response-time commitment is meaningfully better than vague reassurances buried in a support email, but the real test is what happens when a buyer actually invokes the policy. Look for documented examples in independent reviews where the vendor honored a stated policy under pressure rather than quietly negotiating it down at the last minute.

Specific, falsifiable details versus unfalsifiable claims. "Tested by Janoshik Analytical, batch #LB-2024-0312, results published below" is transparency. "Tested by an independent third-party laboratory to the highest pharmaceutical standards" is marketing — every word is technically true in some sense, and none of it is independently verifiable. The same logic applies to manufacturing claims, ownership disclosures, and shipping commitments throughout this market.

No. Responsiveness without resolution is just well-organized stalling. Real support is measured by outcomes: did the missing vial actually get reshipped, did the customs seizure get replaced, did the wrong product actually get refunded. Some of the most aggressive Trustpilot replies in this market come from vendors who reply within minutes but never deliver on what they promise — speed is a necessary signal, not a sufficient one.

Each headline list shows the highest-scoring vendors that cleared baseline eligibility: verifiable shipping into the region (EU-internal or US addresses), a public catalogue, and some form of testing documentation—then the composite score sets the order. Vendors that fail eligibility, refuse test orders, or cannot be verified are left off rather than ranked at the bottom. Beyond the top ten, we currently review twenty-one European vendors and eighteen US vendors in full. See the methodology page for how eligibility is defined end-to-end.

Both weighted composites round to 4.10 from opposite directions. PeptIQ wins on functionality, UX, and platform reach. Smart Peptide Tracker wins on privacy and pricing transparency. Editor's pick goes to the broader product; the specialist pick goes to the privacy-first one.

Each app runs at least 200 scheduled notifications across 30 days, time-zone changes, and intentional offline windows. We log delivery rate, missed doses, sync conflicts, and data persistence. The full per-app log ships alongside each review and is available on request.

We review apps that meet a minimum bar: active development, public store presence, and a working calculator or tracker. If you think we missed one worth scoring, send it via the contact form. The list refreshes quarterly and qualifying entrants get folded into the next round.

No. Every app on this page — and the rubric itself — is a tracking and calculation tool. Apps that drift into a prescribing posture get capped at 1/5 on Safety. Talk to a clinician about protocol choices, dose changes, and any unexpected reactions.